- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01012674
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
May 11, 2016 updated by: Guerbet
Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA
Study Type
Interventional
Enrollment (Actual)
211
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Bloomington, Indiana, United States, 47403
- Guerbet LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, aged more than 18 years
- Strongly suspected of having carotid or vertebral arterial disease
- Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA) examination
Exclusion Criteria:
- Known grade IV or V chronic kidney disease (GFR<30 mL/min/1.73m²)
- Contraindication to MRI
- Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dotarem and TOF MRA
Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
|
Each subject will receive one injection of Dotarem 0.2ml/kg
Other Names:
Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Failure Rate
Time Frame: 2 - 28 days
|
Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).
|
2 - 28 days
|
Sensitivity
Time Frame: 2-42 days
|
Rate of true stenotic segments (i.e. with stenosis >= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).
|
2-42 days
|
Specificity
Time Frame: 2 - 42 days
|
Rate of true non-stenotic segments (i.e.
without stenosis >= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).
|
2 - 42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pierre DESCHE, MD, Guerbet
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
November 12, 2009
First Submitted That Met QC Criteria
November 12, 2009
First Posted (Estimate)
November 13, 2009
Study Record Updates
Last Update Posted (Estimate)
June 16, 2016
Last Update Submitted That Met QC Criteria
May 11, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Intracranial Arterial Diseases
- Cerebral Arterial Diseases
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
Other Study ID Numbers
- DGD-44-049
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Arterial Diseases
-
George Papanicolaou HospitalCompletedCerebral Aneurysm | Cerebral Arterial DiseaseGreece
-
University Hospital, Basel, SwitzerlandCompleted
-
University of Roma La SapienzaNot yet recruitingMiddle Cerebral Artery Occlusion With Cerebral Infarction
-
Xuanwu Hospital, BeijingRecruitingInfarction, Middle Cerebral Artery | Symptomatic Chronic Middle Cerebral Artery OcclusionChina
-
Xuanwu Hospital, BeijingCompletedStroke | Carotid Artery Occlusion | Middle Cerebral Artery OcclusionChina
-
Ege UniversityCompletedCerebral HerniationTurkey
-
All India Institute of Medical Sciences, New DelhiPostgraduate Institute of Medical Education and Research; Sanjay Gandhi Postgraduate... and other collaboratorsCompletedMiddle Cerebral Artery Infarction | Anterior Cerebral Artery InfarctionIndia
-
University of AarhusCompleted
-
University Hospital Center of MartiniqueWithdrawnNervous System Disorders | Cerebral Artery
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownMiddle Cerebral Artery InfarctionMalaysia
Clinical Trials on Dotarem
-
Vanderbilt University Medical CenterChildren's Hospital of Philadelphia; GuerbetCompletedMagnetic Resonance Imaging Contrast AgentsUnited States
-
Northwestern UniversityCompletedVascular DiseasesUnited States
-
Bracco Diagnostics, IncCompleted
-
BayerCompletedNeoplastic CNS LesionsItaly
-
University of ChicagoGuerbetCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaUnited States
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Massachusetts General HospitalWithdrawnContrast Media AllergyUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Massachusetts General HospitalWithdrawn
-
GuerbetCompletedPeripheral Arterial DiseaseFrance